Marie-Laure Boof

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 6

Top Topics

Systemic Lupus Erythematosus

Placebo Controlled

Top Venues

European journal of clinical pharmacology

British journal of clinical pharmacology

Xenobiotica; the fate of foreign compounds in biological systems

This page only lists publications with an associated author ORCID identifier.

Publications

Marie-Laure Boof, Martine Géhin, Christine Voors-Pette, Chih-Hsuan Hsin, Virginie Sippel, Daniel S Strasser, Jasper Dingemanse
Pharmacokinetics, pharmacodynamics, and safety of the novel CXCR3 antagonist ACT-777991: Results from the first-in-human study in healthy adults. British journal of clinical pharmacology (2023)
Marie-Laure Boof, Jasper Dingemanse, Katharina Lederer, Ingo Fietze, Mike Ufer
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 44 (6) (2021)
Marie-Laure Boof, Jasper Dingemanse, Mareile Brunke, Albert Esselmann, Peter Heymer, Olaf Kestermann, Katharina Lederer, Ingo Fietze, Mike Ufer
Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. Journal of sleep research 30 (4) (2021)
Marie-Laure Boof, Jan Jaap van Lier, Stephen English, Hartmut Fischer, Mike Ufer, Jasper Dingemanse
Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P1 receptor modulator in healthy subjects. Xenobiotica; the fate of foreign compounds in biological systems 50 (8) (2020)
Marie-Laure Boof, Atef Halabi, Mike Ufer, Jasper Dingemanse
Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects. European journal of clinical pharmacology 76 (3) (2019)
Marie-Laure Boof, Abir Alatrach, Mike Ufer, Jasper Dingemanse
Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. European journal of clinical pharmacology 75 (2) (2018)